Paul Visintainer to Borrelia burgdorferi
This is a "connection" page, showing publications Paul Visintainer has written about Borrelia burgdorferi.
Connection Strength
0.396
-
Weitzner E, Visintainer P, Wormser GP. Comparison of males versus females with culture-confirmed early Lyme disease at presentation and at 11-20 years after diagnosis. Diagn Microbiol Infect Dis. 2016 Aug; 85(4):493-5.
Score: 0.124
-
Weitzner E, McKenna D, Nowakowski J, Scavarda C, Dornbush R, Bittker S, Cooper D, Nadelman RB, Visintainer P, Schwartz I, Wormser GP. Long-term Assessment of Post-Treatment Symptoms in Patients With Culture-Confirmed Early Lyme Disease. Clin Infect Dis. 2015 Dec 15; 61(12):1800-6.
Score: 0.119
-
Wormser GP, Nowakowski J, Nadelman RB, Visintainer P, Levin A, Aguero-Rosenfeld ME. Impact of clinical variables on Borrelia burgdorferi-specific antibody seropositivity in acute-phase sera from patients in North America with culture-confirmed early Lyme disease. Clin Vaccine Immunol. 2008 Oct; 15(10):1519-22.
Score: 0.073
-
Weitzner E, Visintainer P, Wormser GP. Impact of patient age on clinical features, serologic test reactivity and long-term outcome of culture-confirmed early Lyme disease. Diagn Microbiol Infect Dis. 2017 Dec; 89(4):300-302.
Score: 0.034
-
Wormser GP, Tang AT, Schimmoeller NR, Bittker S, Cooper D, Visintainer P, Aguero-Rosenfeld ME, Ogrinc K, Strle F, Stanek G. Utility of serodiagnostics designed for use in the United States for detection of Lyme borreliosis acquired in Europe and vice versa. Med Microbiol Immunol. 2014 Feb; 203(1):65-71.
Score: 0.026
-
Nowakowski J, McKenna D, Nadelman RB, Bittker S, Cooper D, Pavia C, Holmgren D, Visintainer P, Wormser GP. Blood cultures for patients with extracutaneous manifestations of Lyme disease in the United States. Clin Infect Dis. 2009 Dec 01; 49(11):1733-5.
Score: 0.020